Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
0.9399
-0.0901 (-8.75%)
At close: Nov 19, 2026, 4:00 PM EST
0.9300
-0.0099 (-1.05%)
After-hours: Nov 19, 2026, 4:10 PM EST
Innate Pharma Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Innate Pharma stock has a consensus rating of "Buy" and an average price target of $8.00. The average 1-year stock price forecast is 751.15% higher than the current stock price, while the lowest is $7.00 (+644.76%) and the highest is $9.00 (+857.55%).
Price Target: $8.00 (+751.15%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Innate Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Aug '26 | Sep '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold Downgrades $1 | Hold | Downgrades | $1 | +6.39% | Nov 19, 2026 |
| BTIG | BTIG | Buy Maintains $9 | Buy | Maintains | $9 | +857.55% | Nov 19, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $7 | Buy | Maintains | $7 | +644.76% | Nov 18, 2026 |
Financial Forecast
Revenue This Year
57.12M
from 9.01M
Increased by 534.36%
Revenue Next Year
90.00M
from 57.12M
Increased by 57.54%
EPS This Year
0.23
EPS Next Year
0.91
from 0.23
Increased by 293.48%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.